▶ 調査レポート

遺伝子治療のグローバル市場(2023~2028):がん、代謝性疾患、眼科疾患、脊髄性筋萎縮症、その他

• 英文タイトル:Gene Therapy Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Mordor Intelligenceが調査・発行した産業分析レポートです。遺伝子治療のグローバル市場(2023~2028):がん、代謝性疾患、眼科疾患、脊髄性筋萎縮症、その他 / Gene Therapy Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028) / MRC2303K043資料のイメージです。• レポートコード:MRC2303K043
• 出版社/出版日:Mordor Intelligence / 2023年2月
• レポート形態:英文、PDF、124ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥688,750 (USD4,750)▷ お問い合わせ
  Corporate License¥1,268,750 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Mordor Intelligence社の調査レポートでは、世界の遺伝子治療市場規模が、予測期間中、CAGR 25.71%で増大すると予測されています。本レポートでは、遺伝子治療の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患別(がん、代謝性疾患、眼科疾患、脊髄性筋萎縮症、その他)分析、技術別(アデノウィルスベクター、アデノ随伴ウイルス、レンチウイルス、レトロウィルスベクター、その他)分析、地域別(アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン)分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Amgen Inc.、Biogen Inc.、Bluebird Bio Inc.、Gilead Sciences Inc. (Kite Pharma)、Novartis AG、F. Hoffmann-La Roche Ltd (Spark Therapeutics)、UniQure NV、Abeona Therapeutics Inc.、Generation Bio、Poseida Therapeutics、Astellas Pharma、Voyager Therapeutics Inc.などの企業情報が含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の遺伝子治療市場規模:疾患別
- がんにおける市場規模
- 代謝性疾患における市場規模
- 眼科疾患における市場規模
- 脊髄性筋萎縮症における市場規模
- その他疾患における市場規模
・世界の遺伝子治療市場規模:技術別
- アデノウィルスベクターにおける市場規模
- アデノ随伴ウイルスにおける市場規模
- レンチウイルスにおける市場規模
- レトロウィルスベクターにおける市場規模
- その他技術における市場規模
・世界の遺伝子治療市場規模:地域別
- 北米の遺伝子治療市場規模
アメリカの遺伝子治療市場規模
カナダの遺伝子治療市場規模
メキシコの遺伝子治療市場規模

- ヨーロッパの遺伝子治療市場規模
ドイツの遺伝子治療市場規模
イギリスの遺伝子治療市場規模
フランスの遺伝子治療市場規模

- アジア太平洋の遺伝子治療市場規模
中国の遺伝子治療市場規模
日本の遺伝子治療市場規模
インドの遺伝子治療市場規模

- 南米/中東の遺伝子治療市場規模
南アフリカの遺伝子治療市場規模
ブラジルの遺伝子治療市場規模
アルゼンチンの遺伝子治療市場規模

・競争状況
・市場機会・将来動向

The gene therapy market is projected to register a CAGR of 25.71% during the forecast period.

The COVID-19 pandemic had a positive effect on the gene therapy market. Gene and cell therapy technology were extensively used in developing vaccines to treat COVID-19. For example, in January 2021, vaccine candidates developed by Mass General Brigham were made by utilizing gene-therapy technology that elicited robust immune responses in animal models for the treatment of COVID-19. The vaccine candidate was named AAVCOVID, and the researchers received a USD 2.1 million grant to further develop the technology from the Bill & Melinda Gates Foundation. The developed vaccine was far more convenient than the ones sold on the market, as it had a single dose and could be stored at room temperature. Also, per a January 2021 published article in Hindawi Journal, the treatment of coronavirus from the perspective of RNA interference-based gene therapy offered a more direct approach to combating viral genes and has a promising future. Thus, the COVID-19 pandemic led to an increased demand for gene-based therapy for COVID-19.

The major factors propelling the market’s growth include technological advancements, rising investments in research and development, and the growing prevalence of target diseases.

Research and development (R&D) investment is also expected to affect the market significantly. Several companies aim to build a gene therapy platform with a strategy focused on establishing a transformational portfolio through in-house capabilities and enhancing those capabilities through strategic collaborations, expansion of R&D activities, and potential licensing, merger, and acquisition activities. For instance, in January 2022, the Cystic Fibrosis Foundation reported investing in SalioGen Therapeutics to support the company’s preclinical research into novel gene therapy for cystic fibrosis. Salonen’s Gene Coding approach is designed to turn on, turn off, or modify the function of any gene in the genome. Furthermore, in March 2021, ElevateBio, one of the leading biotech companies focused on gene-based therapies, raised USD 525 million to advance its cell and gene therapy technologies.

In addition, the rise in approvals for gene therapies from international regulatory agencies is expected to drive market growth. For instance, in August 2022, the USFDA approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for treating adult and pediatric patients with beta-thalassemia. Such approvals are expected to drive market growth due to the rise in the development of gene therapies.

However, the lack of standard regulations and the high price of products hinder the gene therapy market’s growth.

Gene Therapy Market Trends

Cancer is Expected to Hold Significant Market Share in the Indication Segment over the Forecast Period

The factors boosting segment growth are the increasing burden of cancer disorder, the growing focus on research to develop an effective cancer treatment, and rising investments in cancer research.

For instance, according to the ACS ‘Cancer Facts & Figures 2022’, around 1,918,030 new cancer cases and 609,360 deaths due to cancers are estimated to be reported in the United States in 2022. In the treatment of cancer, various gene therapy strategies are currently employed. These include anti-angiogenic gene therapy, pro-drug activating suicide gene therapy, gene therapy-based immune modulation, oncolytic virotherapy, correction/compensation of gene defects, antisense, genetic manipulation of apoptotic and tumor invasion pathways, and RNAi strategies. The cancer types, such as brain, lung, breast, pancreatic, liver, colorectal, prostate, bladder, head and neck, skin, ovarian, and renal cancer, have been the target of these therapies.

A growing focus on developing effective therapies for cancer is also contributing to the market growth. For instance, in March 2021, the USFDA approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to or whose disease has returned after at least four last lines (different types) of treatment. Abecma is the first cell-based gene therapy approved by the FDA for treating multiple myeloma.

Many key players in the market are focused on adopting strategies, such as mergers and acquisitions, on enhancing their product portfolio, which is expected to propel market growth over the forecast period. For instance, in June 2021, CyGenica secured funding from SOSV Investments LLC, a venture capital company, to accelerate cancer and rare genetic disease therapy.

Thus, such developments significantly contribute to the overall market’s growth.

North America Dominates the Market and is Expected to do Same over the Forecast Period.

Within North America, the United States has held a major share of the market. The major factors fueling the market growth are the increasing number of investments by the government, advancements in research and development about gene therapy, and the growing prevalence of target diseases.

For instance, as per the United States Center for Disease Control and Prevention article on spinal muscular atrophy (SMA) updated in December 2021, SMA is a genetic disorder that affects around 1 in every 10,000 people. Therefore, it is one of the most common rare diseases. The numbers indicate the growing demand for gene therapy in the United States. In May 2022, the FDA approved the drug, Evrysdi for babies under two months old with spinal muscular atrophy. Evrysdi is an SMN-enhancing therapy that works by targeting the SMN2 gene. Such product approvals in the region are adding to the growth of the market.

Several initiatives are being launched about gene therapy. For instance, as per an October 2021 update by the National Institutes of Health (NIH), the NIH, USFDA, 10 pharmaceutical companies, and 5 non-profit organizations have partnered to accelerate the development of gene therapies for the 30 million Americans who suffer from a rare disease. Such initiatives are anticipated to increase the demand for gene therapy, thereby contributing to market growth.

In addition, rising investments form the Government of United States is also expected to drive the growth of the market growth. For instance, the NIH funding on Gene Therapy in the United States is USD 403 million and USD 481 million in the year 2020 and 2021 respectively. The rising investment in the gene therapy in the United States will lead rise in development of gene therapies in this region, driving the market growth.

Thus, due to the above-mentioned developments, the market is expected to witness significant growth over the forecast period.

Gene Therapy Market Competitor Analysis

The gene therapy market is highly competitive and consists of several significant players. Companies like Amgen Inc., Bluebird Bio, Gilead Sciences, Inc., Novartis AG, Orchard Therapeutics, Sibiono GeneTech Co. Ltd, Spark Therapeutics (Roche AG), and UniQure NV hold a substantial market share. They have various strategic alliances, such as collaborations and acquisitions, along with the launch of advanced products to secure their position in the global market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
レポート目次

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Investments in Research and Development
4.2.2 Technological Advancements
4.2.3 Growing Prevalence of Target Diseases like Cancer
4.3 Market Restraints
4.3.1 Lack of Standard Regulations
4.3.2 High Price of Products
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value- USD million)
5.1 By Indication
5.1.1 Cancer
5.1.2 Metabolic Disorders
5.1.3 Eye Disorders
5.1.4 Spinal Muscular Atrophy
5.1.5 Other Indications
5.2 By Technology
5.2.1 Adeno Virus Vector
5.2.2 Adeno-associated Virus Vector
5.2.3 Lentiviral Vector
5.2.4 Retroviral Vector
5.2.5 Herpes Virus Vector
5.2.6 Other Technologies
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 Biogen Inc.
6.1.3 Bluebird Bio Inc.
6.1.4 Gilead Sciences Inc. (Kite Pharma)
6.1.5 Novartis AG
6.1.6 F. Hoffmann-La Roche Ltd (Spark Therapeutics)
6.1.7 UniQure NV
6.1.8 Abeona Therapeutics Inc.
6.1.9 Generation Bio
6.1.10 Poseida Therapeutics
6.1.11 Astellas Pharma
6.1.12 Voyager Therapeutics Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS